期刊
VACCINES
卷 10, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/vaccines10040530
关键词
Trisomy 21; down syndrome; COVID-19; SARS-CoV-2; BNT162b2; mRNA-1273; ChAdOx1 nCoV-19; Ad26.COV2.S; vaccine hesitancy
资金
- Down Syndrome Affiliates in Action
- Down Syndrome Medical Interest Group-USA
- GiGi's Playhouse
- Jerome Lejeune Foundation
- LuMind IDSC Foundation
- The Matthew Foundation
- National Down Syndrome Society
- National Task Group on Intellectual Disabilities and Dementia Practices
- HERCULES Center [NIEHS P30ES019776]
- Library Information Technology Services grant support [UL1 TR000424]
- Alana USA Foundation
- Awakening Angels Foundation
- Infectious Diseases Society of America (IDSA)
- Centre for Genomic Regulation Severo Ochoa excellence grant
- CIBER of Rare Diseases, DURSI [2017SGR595]
- Agencia Estatal de Investigacion [PID2019-110755RB-I00/AEI]
- Spanish Ministry of Science, Innovation and Universities (MSIU)
- Centro de Excelencia Severo Ochoa
- MRC [MR/S011277/1, MR/S005145/1, MR/R024901/1]
- Lumind IDSC
- The Lejeune Foundation
- European Commission [GO-DS21-848077]
- National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust
- ISCIII
- EDER [PT17/0009/0014]
- AEI [CEX2018-000782-M]
- Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya [2017 SGR 00519]
- Fondo de Investigaciones Sanitarias (Ministerio de Economia y Competitividad (Instituto de Salud Carlos III)) [PI19/00634]
- European Regional Development Fund (ERDF) A way to make Europe
- Fondation Jerome Lejeune [2021a-2069]
- CERCA (GenCat)
- MRC [MR/S005145/1] Funding Source: UKRI
Individuals with Down syndrome have a high uptake of COVID-19 vaccines with minimal side effects and breakthrough infections. Unvaccinated individuals were often younger, previously recovered from COVID-19, and not vaccinated against other recommended vaccines.
Individuals with Down syndrome (DS) are among the groups with the highest risk for severe COVID-19. Better understanding of the efficacy and risks of COVID-19 vaccines for individuals with DS may help improve uptake of vaccination. The T21RS COVID-19 Initiative launched an international survey to obtain information on safety and efficacy of COVID-19 vaccines for individuals with DS. De-identified survey data collected between March and December 2021 were analyzed. Of 2172 individuals with DS, 1973 (91%) had received at least one vaccine dose (57% BNT162b2), 107 (5%) were unvaccinated by choice, and 92 (4%) were unvaccinated for other reasons. Most participants had either no side effects (54%) or mild ones such as pain at the injection site (29%), fatigue (12%), and fever (7%). Severe side effects occurred in <0.5% of participants. About 1% of the vaccinated individuals with DS contracted COVID-19 after vaccination, and all recovered. Individuals with DS who were unvaccinated by choice were more likely to be younger, previously recovered from COVID-19, and also unvaccinated against other recommended vaccines. COVID-19 vaccines have been shown to be safe for individuals with DS and effective in terms of resulting in minimal breakthrough infections and milder disease outcomes among fully vaccinated individuals with DS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据